Dr. Bengt Höpken completed his biology studies at the Karl-Ruprechts University in Heidelberg. After his successful doctorate on the eicosanoid metabolism in keratinocytes at the German Cancer Research Centre in 1998, he worked as a scientist at the Institute of Immunology at the University of Heidelberg.
In 1999 Bengt moved to the field of drug development. He held various positions at Byk Gulden/Altana Pharma, Schwarz Pharma and since 2008 at UCB BioSciences GmbH.
In his current position as Clinical Program Director, his focus is on the development of an anti-TNF inhibitor in several immunological indications and he works closely together with a transversal team of experts. He led the submission and approval of this drug in the indications of psoriatic arthritis and axial spondyloarthritis.